We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Video Player

Immunology for
a Better Future

Learn More

Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Learn More

We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.

Learn More

Advancing Therapeutic
Solutions

Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.

Learn More

Focused on Improving
Lives

We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.

Learn More

Key Highlights

NYSE American:
AIM
03/24/2025 4:03 PM
$0.14